Semaglutide Vs Liraglutide: Complete Comparison
Semaglutide produces roughly twice the weight loss of liraglutide (15-17% vs 5-8%) and requires only one injection per week instead of daily shots, making it the clear upgrade for most patients considering a GLP-1 medication.
Liraglutide was the pioneer. Approved as Saxenda for weight management in 2014, it was the first GLP-1 receptor agonist that proved these medications could produce meaningful weight loss. Semaglutide, a newer and more potent GLP-1 agonist, has since taken center stage. At Form Blends, we think it is important to understand both, especially since some patients still encounter liraglutide as an option from their providers.
| Feature | Semaglutide | Liraglutide |
|---|---|---|
| Drug Class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Brand Names | Ozempic (diabetes), Wegovy (weight loss), Rybelsus (oral/diabetes) | Victoza (diabetes), Saxenda (weight loss) |
| Injection Frequency | Once weekly | Once daily |
| Maximum Dose (weight loss) | 2.4 mg/week (Wegovy) | 3.0 mg/day (Saxenda) |
| Average Weight Loss | ~15-17% | ~5-8% |
| Half-Life | ~7 days (supports weekly dosing) | ~13 hours (requires daily dosing) |
| Cardiovascular Indication | Yes (SELECT trial, Wegovy) | No (LEADER trial showed benefit for Victoza/diabetes only) |
| Typical Monthly Cost | $1,300-$1,400/mo (brand) (brand) / $150-$500 (compounded) | Contact provider for current pricing |
How Semaglutide Works
Semaglutide is a second-generation GLP-1 receptor agonist that was designed to improve upon liraglutide in several important ways. Like liraglutide, it mimics the natural GLP-1 hormone to suppress appetite, slow gastric emptying, and enhance insulin secretion. The key molecular advancement is semaglutide's dramatically longer half-life .
Through strategic modifications to the GLP-1 peptide structure, Novo Nordisk engineers gave semaglutide a half-life of approximately one week, compared to liraglutide's 13 hours. This extended duration means semaglutide provides steady, consistent receptor activation between weekly injections, rather than the peaks and troughs associated with daily liraglutide dosing.
The result is not just more convenient dosing. The sustained receptor activation appears to produce stronger and more consistent appetite suppression, which may partly explain semaglutide's superior weight loss results.
How Liraglutide Works
Liraglutide was the first GLP-1 agonist developed by Novo Nordisk and served as the foundation for semaglutide's development. It activates the same GLP-1 receptors and produces the same general effects: appetite suppression, delayed gastric emptying, and improved glycemic control .
However, liraglutide's shorter half-life means it must be injected daily. It is available as Victoza (1.8 mg daily for diabetes) and Saxenda (3.0 mg daily for weight management). Saxenda received FDA approval for chronic weight management in December 2014 and was the go-to GLP-1 weight loss medication for several years before Wegovy arrived.
Liraglutide's titration schedule runs through five daily dose levels (0.6, 1.2, 1.8, 2.4, and 3.0 mg) over five weeks, which is faster than semaglutide's titration but still gradual enough to manage GI side effects for most patients.
Efficacy Comparison: Weight Loss Results
This is a clear win for semaglutide. The STEP 1 trial showed semaglutide 2.4 mg produced average weight loss of 14.9% over 68 weeks . The SCALE trial showed liraglutide 3.0 mg produced average weight loss of 8.0% over 56 weeks .
The most definitive comparison comes from the STEP 8 trial, which directly compared semaglutide 2.4 mg weekly to liraglutide 3.0 mg daily in the same patient population. Semaglutide produced 15.8% weight loss versus 6.4% for liraglutide over 68 weeks . That means semaglutide produced roughly 2.5 times more weight loss in a head-to-head comparison.
The proportion of patients achieving clinically meaningful weight loss thresholds also strongly favored semaglutide. In STEP 8, 70% of semaglutide patients lost at least 10% of body weight, compared to 26% of liraglutide patients .
By essentially every measure, semaglutide is the more effective weight loss medication.
Side Effects Comparison
As GLP-1 agonists, both share a similar side effect profile:
- Nausea: Common with both. In STEP 8, nausea rates were similar (approximately 20-44% depending on the study) .
- Diarrhea: Reported at comparable rates.
- Vomiting: Somewhat more frequent with semaglutide in head-to-head data.
- Constipation: Common with both.
- Injection frequency fatigue: Liraglutide requires 365 injections per year; semaglutide requires 52. This is a significant practical advantage for semaglutide.
Both medications carry the same serious risk warnings: pancreatitis, gallbladder disease, kidney injury, and thyroid C-cell tumor risk based on animal studies . Both are contraindicated in patients with medullary thyroid carcinoma or MEN-2.
In the STEP 8 trial, the discontinuation rate due to GI adverse events was higher with semaglutide (3.2%) than liraglutide (1.9%), suggesting that semaglutide may be slightly harder to tolerate for some patients . However, most experts consider this an acceptable trade-off given the dramatically better efficacy.
One area where liraglutide has a unique advantage is in the rare patient who needs the medication to clear the system quickly. Liraglutide's 13-hour half-life means it is mostly gone within 2-3 days of stopping. Semaglutide, with its week-long half-life, takes several weeks to fully wash out. For patients planning surgery, becoming pregnant, or managing a side effect emergency, liraglutide's shorter duration can be beneficial.
Adherence is another important practical consideration. Studies consistently show that patients are more likely to stay on once-weekly medications than once-daily ones . Missing a daily injection is easy to do, and inconsistent dosing undermines both efficacy and side effect management. Semaglutide's weekly schedule removes this variable. One injection, same day each week, and you are covered for seven days.
Cost Comparison
Saxenda (liraglutide for weight loss) costs approximately Contact provider for current pricing per month. Wegovy (semaglutide for weight loss) costs approximately $1,300-$1,400/mo (brand) per month. Prices are in a similar range for both brand-name products.
Given that semaglutide produces roughly 2.5 times more weight loss at a comparable price, its cost-effectiveness is significantly better. You pay a similar monthly rate for dramatically better results.
Compounded semaglutide through Form Blends costs $150 to $500 per month, providing the superior molecule at a fraction of either brand-name price. Compounded liraglutide is less commonly available through telehealth platforms because semaglutide has largely superseded it.
Who Is Semaglutide Best For?
- Essentially any patient who would otherwise be considering liraglutide (semaglutide is superior on most measures)
- Patients who prefer weekly injections over daily
- Those seeking maximum weight loss from a GLP-1 medication
- Patients who want the cardiovascular risk reduction benefit
- Anyone who values the convenience of less frequent dosing
Who Is Liraglutide Best For?
- Patients who tried semaglutide and could not tolerate it (switching to a daily, lower-peak medication may improve tolerability for some)
- Those with specific insurance coverage for Saxenda but not Wegovy
- Adolescent patients (Saxenda is approved for weight management in patients aged 12+, which was approved before Wegovy's adolescent indication)
- Patients who for medical reasons need a shorter-acting GLP-1 (rare situation)
Frequently Asked Questions
Is semaglutide basically a better version of liraglutide?
In most respects, yes. Semaglutide was specifically developed to be a next-generation improvement over liraglutide. It produces more weight loss, requires less frequent injections, and has a more favorable efficacy-to-side-effect ratio. The head-to-head STEP 8 trial confirmed semaglutide's superiority on every major efficacy outcome. Liraglutide paved the way for the entire GLP-1 weight loss revolution, but semaglutide has clearly surpassed it.
Should I switch from Saxenda to semaglutide?
If you are on liraglutide (Saxenda) and have not reached your weight loss goals, switching to semaglutide is a reasonable option to discuss with your physician. Many patients who plateau on liraglutide achieve further weight loss after switching to semaglutide.
Can I switch directly from liraglutide to semaglutide?
Yes, though your doctor will typically start semaglutide at its lowest dose (0.25 mg) and titrate up, even if you were on a full dose of liraglutide. Since both are GLP-1 agonists, the transition is generally smooth, but the titration helps manage any differences in side effect profile.
Are both medications made by the same company?
Yes. Novo Nordisk manufactures both liraglutide (Victoza, Saxenda) and semaglutide (Ozempic, Wegovy, Rybelsus). Semaglutide was developed as the successor to liraglutide.
Does liraglutide have any advantage over semaglutide?
Liraglutide's main advantages are its shorter half-life (useful if you need to clear the drug quickly for surgery or pregnancy planning), its long track record in adolescent patients, and the fact that some patients who cannot tolerate semaglutide may do better on the shorter-acting liraglutide. These are niche situations, but they are real.
Does Form Blends offer semaglutide?
Yes. Form Blends offers physician-supervised compounded semaglutide programs at prices significantly lower than brand-name Wegovy or Saxenda. Our medical team will help you determine the right medication and dose for your goals.
Upgrade to the most effective GLP-1 available. Start your free consultation with Form Blends today and access physician-supervised semaglutide therapy at a price that makes long-term treatment sustainable.